Tech Company Financing Transactions

Pionyr Immunotherapeutics Funding Round

Pionyr Immunotherapeutics, based in San Francisco, secured $62 million from New Enterprise Associates, Mission Bay Capital and OrbiMed.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

2 Tower Pl. 800
San Francisco, CA 94080
USA

Phone

(650) 825-6140

Website

www.pionyrtx.com

Email Address

[email protected]

Overview

Pionyr develops drugs to perform exceptional fine-tuning of immune responses. This goal addresses a current and justified excitement about immunotherapy and introduces technology to rapidly identify and target novel arms of the immune response, within the tumor microenvironment (TME).

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Steven James

        

Chief Financial Officer

Monte Montgomery

        

Chief Medical Officer

Leonard Reyno

        

Chief Scientific Officer

Michel Streuli

        

Vice President

Kevin Baker

        

Vice President

Evan Greger

        

VP - Bus. Development

Alicia Levey

        

VP - Operations

Michael Ellis

        

Browse more venture capital transactions:

Prev: 12/14/2017: FollowAnalytics venture capital transaction
Next: 12/15/2017: Glo Station venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary